M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B BioSpaceDizal Pharmaceutical's Zegfrovy is approved in the U.S.OncologyRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) BioSpace Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis and Chai Discovery collaborate on antibody identificationNext: Spero snaps up Innovent immunology drug in strategic pivot Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
